Diffuse intrinsic pontine glioma

What is Diffuse intrinsic pontine glioma?

Diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive type of brain tumor that develops in the pons, a critical region of the brainstem that controls essential functions like breathing, heart rate, and movement coordination. This cancer primarily affects children, typically between ages 5-9 years, and represents one of the most challenging pediatric brain tumors to treat. With a prevalence of approximately 2-3 cases per million children, DIPG accounts for about 10-15% of all pediatric brain tumors but has historically carried a very poor prognosis due to its location and aggressive nature.

Key statistics

Symptoms

Early symptoms: Double vision, difficulty walking, facial weakness, speech problems, headaches, nausea and vomiting.

The symptoms of DIPG typically develop rapidly over weeks to months due to the tumor’s aggressive growth within the confined space of the brainstem. Early signs often include cranial nerve palsies, which manifest as double vision (diplopia), facial drooping or weakness, difficulty swallowing, and changes in speech or voice quality. Children may experience ataxia, appearing unsteady while walking or having difficulty with coordination and balance.

As the tumor progresses, long-tract signs emerge, including weakness on one or both sides of the body, abnormal reflexes, and problems with fine motor skills. Increased intracranial pressure may cause persistent headaches, particularly in the morning, along with nausea and vomiting. Some children develop behavioral changes, difficulty concentrating, or personality alterations. In advanced stages, breathing difficulties, severe weakness, and loss of consciousness may occur as the tumor affects vital brainstem functions.

Submit Your Paper

Causes and risk factors

DIPG is caused by somatic mutations, particularly the H3K27M mutation found in histone H3.3 or H3.1 genes, which occurs in approximately 80% of cases. These mutations are acquired during the child’s lifetime and are not inherited from parents. The H3K27M mutation disrupts normal gene regulation, leading to uncontrolled cell growth and tumor formation in the brainstem.

Unlike many cancers, DIPG has no known environmental risk factors, radiation exposure history, or lifestyle factors that increase risk. The tumor appears to arise spontaneously during childhood development. There is no evidence of familial clustering, and having a family history of cancer does not increase a child’s risk of developing DIPG. Research suggests that the mutations may occur during critical periods of brain development, but the exact triggers remain unknown.

Prevention

There is currently no known way to prevent DIPG, as it results from spontaneous somatic mutations that occur during childhood development. Unlike hereditary cancer syndromes, DIPG is not caused by inherited genetic mutations, so genetic testing of parents or family members is not recommended for prevention purposes.

Prenatal screening cannot detect DIPG, as the tumor develops after birth during childhood. Research into early detection biomarkers is ongoing, but currently no screening programs exist for asymptomatic children. The focus remains on prompt recognition of symptoms and rapid diagnosis to begin treatment as quickly as possible.

Complications

Without treatment, DIPG progresses rapidly, typically leading to death within 6-9 months due to brainstem compression and dysfunction of vital functions. The tumor’s location makes it impossible to surgically remove, and its growth causes progressive neurological deterioration.

Complications include progressive weakness leading to paralysis, severe difficulty swallowing that may require feeding tube placement, respiratory compromise requiring ventilatory support, and loss of consciousness. Even with treatment, most children experience gradual loss of motor function, speech difficulties, and cognitive changes. Seizures may occur, though they are less common than in other brain tumors. The emotional and psychological impact on both patients and families is profound, requiring comprehensive supportive care throughout the disease course.

Diagnosis

DIPG diagnosis relies primarily on magnetic resonance imaging (MRI) of the brain, which typically shows a characteristic infiltrative tumor within the pons that appears bright on T2-weighted images and involves at least 50% of the pontine tissue. The tumor often demonstrates a “engulfing” pattern around normal brainstem structures.

Clinical presentation combined with typical MRI findings is often sufficient for diagnosis. However, tissue biopsy is increasingly performed when safe and feasible, allowing for molecular characterization including testing for the H3K27M mutation through immunohistochemistry or DNA sequencing. Advanced MRI techniques like diffusion tensor imaging and MR spectroscopy may provide additional diagnostic information.

Lumbar puncture is generally avoided due to increased intracranial pressure risk. Routine blood tests are typically normal, though they may be performed to assess overall health status before treatment. Neurological examination documenting cranial nerve function, motor strength, coordination, and reflexes is essential for baseline assessment and monitoring disease progression.

Treatment

Standard treatment for DIPG involves focal radiation therapy, typically delivered as 54-60 Gray over 6 weeks, which can provide temporary symptom improvement and modest survival extension. Dexamethasone or other corticosteroids are often used to reduce tumor-associated swelling and manage symptoms.

Numerous experimental treatments are being investigated, including targeted therapies, immunotherapy approaches, and convection-enhanced delivery systems that bypass the blood-brain barrier. Bevacizumab has been studied in clinical trials with limited success. Histone deacetylase inhibitors like panobinostat and vorinostat are being evaluated based on the tumor’s epigenetic alterations.

Supportive care is crucial and may include physical therapy, occupational therapy, speech therapy, nutritional support, and palliative care services. Clinical trial participation is strongly encouraged, as conventional chemotherapy has shown limited effectiveness against DIPG.

Prognosis

DIPG carries one of the poorest prognoses among pediatric cancers, with median survival of 9-12 months from diagnosis and less than 5% of patients surviving beyond 5 years. Most children experience initial improvement with radiation therapy, but the tumor typically recurs within 6-9 months.

Factors associated with slightly better outcomes include younger age at diagnosis (under 3 years), longer duration of symptoms before diagnosis, and certain molecular characteristics. However, even in the most favorable cases, long-term survival remains extremely rare. Quality of life during treatment varies, with many children able to return to school and activities during periods of symptom control.

The devastating prognosis has galvanized research efforts and patient advocacy, leading to increased funding and novel therapeutic approaches that offer hope for improved outcomes in the future.

Quality of life

Managing quality of life for children with DIPG requires a comprehensive, family-centered approach. During periods of symptom control, many children can attend school with appropriate accommodations, engage in modified physical activities, and maintain social relationships. Fatigue management is important, with rest periods scheduled around daily activities.

Nutritional support may require texture modifications or feeding assistance as swallowing becomes difficult. Physical therapy helps maintain mobility and prevent contractures, while occupational therapy addresses fine motor skills and adaptive equipment needs. Speech therapy supports communication as the disease progresses.

Psychological support for both patients and families is essential, including child life specialists, counselors, and support groups. Creating meaningful experiences and memory-making opportunities becomes a priority for families. Palliative care teams can help optimize comfort and address symptoms while supporting the child’s goals and preferences.

Pregnancy and fertility

Fertility and pregnancy considerations are generally not applicable for DIPG patients, as this cancer primarily affects young children before reproductive age. However, for adolescent patients who survive into adulthood, radiation therapy to the brain may affect hormonal function and fertility through effects on the hypothalamic-pituitary axis.

Radiation treatment can potentially impact growth hormone production, thyroid function, and reproductive hormone regulation. Long-term survivors require endocrine monitoring and may need hormone replacement therapy. Fertility preservation discussions are rarely relevant due to the young age of patients and poor prognosis, but should be addressed if appropriate for adolescent patients.

Children

DIPG is primarily a pediatric disease, with unique considerations for affected children and their families. Age-appropriate communication about the diagnosis and treatment is crucial, often involving child life specialists who can help explain complex medical concepts using developmentally suitable language and tools.

School coordination is important during treatment, with many children able to continue their education with accommodations during stable periods. Educational teams should be informed about potential cognitive changes, fatigue, and physical limitations. Social work support helps families navigate insurance, disability benefits, and community resources.

Siblings require special attention and support, as they may experience fear, confusion, and disrupted family routines. Family counseling and sibling support groups can be beneficial. Creating normalcy within the family structure while accommodating medical needs is an ongoing challenge that requires professional guidance and community support.

When to see a doctor

Seek immediate medical attention if a child develops rapid onset of double vision, facial weakness, difficulty walking or balance problems, persistent morning headaches with vomiting, or any combination of neurological symptoms. While these symptoms can have various causes, the rapid progression typical of DIPG warrants urgent evaluation.

Emergency care is needed for severe headaches, repeated vomiting, difficulty breathing, loss of consciousness, or significant changes in alertness or behavior. These may indicate increased intracranial pressure or brainstem compression requiring immediate intervention.

For children already diagnosed with DIPG, contact the medical team promptly for new or worsening symptoms, breathing difficulties, swallowing problems, significant weakness changes, or seizures. Regular monitoring visits are essential even when symptoms are stable.

Regional context

Limited epidemiological data exists specifically for DIPG prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The global prevalence of 2-3 per million children annually likely applies to these regions, but local cancer registries may provide more precise data.

Access to specialized pediatric neuro-oncology care and advanced radiation therapy equipment may vary across the region. International collaboration and telemedicine consultations can help ensure appropriate diagnosis and treatment planning. We invite healthcare providers and researchers from these regions to contribute local epidemiological data and treatment experience to the Global Medical Journal to improve regional understanding of DIPG patterns and outcomes.

Research and clinical trials

DIPG research has intensified significantly, with numerous clinical trials investigating novel approaches. Current research focuses on targeted therapies against the H3K27M mutation, immunotherapy including CAR-T cell treatments, and drug delivery methods that overcome the blood-brain barrier.

Promising areas include ONC201, a drug that has shown activity in H3K27M-mutant tumors, and various immunotherapeutic approaches including peptide vaccines and checkpoint inhibitors. Convection-enhanced delivery allows direct drug administration to the brainstem, bypassing systemic barriers.

International collaborative efforts like the DIPG Registry and the Pediatric Brain Tumor Consortium coordinate research efforts and standardize treatment protocols. Families can search for current trials at ClinicalTrials.gov or through major pediatric cancer centers. Tissue donation through autopsy programs has been crucial for advancing understanding of DIPG biology and developing new treatments.

Frequently asked questions

Can DIPG be cured?

Currently, there is no cure for DIPG, and the prognosis remains very poor with less than 5% long-term survival. However, intensive research efforts are underway investigating new treatments that may improve outcomes in the future.

Why can’t DIPG be surgically removed?

DIPG tumors grow diffusely throughout the brainstem, infiltrating normal tissue that controls vital functions like breathing and heart rate. Surgical removal would cause severe neurological damage or death, making surgery impossible except for rare focal tumors.

Is DIPG hereditary?

No, DIPG is not inherited from parents. It results from somatic mutations (H3K27M) that occur during the child’s development. Family history does not increase risk, and genetic counseling for future pregnancies is not typically necessary.

Do clinical trials offer hope for DIPG patients?

Yes, clinical trials are crucial for DIPG patients and represent the best hope for improved treatments. Many families choose trial participation to access experimental therapies while contributing to research that may help future patients.

How can families cope with a DIPG diagnosis?

Coping requires comprehensive support including palliative care teams, psychological counseling, support groups, and focusing on quality time together. Many families find meaning in advocacy efforts and supporting research while maximizing positive experiences during treatment.

Support and resources

Patient Organizations:
– The DIPG Collaborative: dipgcollaborative.org
– ChadTough Foundation: chadtough.org
– Michael Mosier Defeat DIPG Foundation: defeatdipg.org

International Resources:
– Orphanet: orpha.net
– National Organization for Rare Disorders (NORD): rarediseases.org
– EURORDIS: eurordis.org
– Pediatric Brain Tumor Foundation: curethekids.org

Related conditions

Glioblastoma
Medulloepithelioma
Brainstem glioma
Pediatric high-grade glioma
Atypical teratoid rhabdoid tumor

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.